{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:54:40Z","timestamp":1761396880028,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T00:00:00Z","timestamp":1722729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T00:00:00Z","timestamp":1722729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40487-024-00291-6","type":"journal-article","created":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T13:02:00Z","timestamp":1722776520000},"page":"565-583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["From Triple- to Penta-Exposed Multiple Myeloma: A Real-World Study in a Medicare Population"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5493-1925","authenticated-orcid":false,"given":"Thomas E.","family":"Delea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiufei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn S.","family":"Kroog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzhen","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Moynahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Sabater Anaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Rodriguez Lorenc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,4]]},"reference":[{"key":"291_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2217\/fon-2020-1003","volume":"17","author":"D Madduri","year":"2021","unstructured":"Madduri D, Hagiwara M, Parikh K, et al. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA. Future Oncol. 2021;17:503\u201315.","journal-title":"Future Oncol"},{"key":"291_CR2","unstructured":"American Cancer Society. Cancer facts & figures 2020. Available at https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2020\/cancer-facts-and-figures-2020.pdf. Accessed 6 June 2024."},{"key":"291_CR3","unstructured":"Drugs.com. Find drugs & conditions. Available at https:\/\/www.drugs.com\/. Accessed 6 June 2024."},{"key":"291_CR4","first-page":"70","volume":"11","author":"DA Kaplan","year":"2022","unstructured":"Kaplan DA. Multiple myeloma: top 10 advances in the past 10 years. Target Ther Oncol. 2022;11:70.","journal-title":"Target Ther Oncol"},{"key":"291_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.12703\/r\/11-28","volume":"11","author":"A Bobin","year":"2022","unstructured":"Bobin A, Leleu X. Recent advances in the treatment of multiple myeloma: a brief review. Fac Rev. 2022;11:28.","journal-title":"Fac Rev"},{"key":"291_CR6","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/jha2.739","volume":"4","author":"J Richter","year":"2023","unstructured":"Richter J, Pan D, Salinardi T, Rice MS. Real-world multiple myeloma front-line treatment and outcomes by transplant in the United States. EJHaem. 2023;4:984\u201394.","journal-title":"EJHaem"},{"key":"291_CR7","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma. Version 2.2020."},{"key":"291_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175:252\u201364.","journal-title":"Br J Haematol"},{"key":"291_CR9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/ejh.13426","volume":"105","author":"G Afram","year":"2020","unstructured":"Afram G, Gran C, Borg Bruchfeld J, et al. Impact of performance status on overall survival in patients with relapsed and\/or refractory multiple myeloma: real-life outcomes of daratumumab treatment. Eur J Haematol. 2020;105:196\u2013202.","journal-title":"Eur J Haematol"},{"key":"291_CR10","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/ejh.13046","volume":"100","author":"M Pick","year":"2018","unstructured":"Pick M, Vainstein V, Goldschmidt N, et al. Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis. Eur J Haematol. 2018;100:494\u2013501.","journal-title":"Eur J Haematol"},{"key":"291_CR11","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266\u201375.","journal-title":"Leukemia"},{"key":"291_CR12","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.3390\/cancers15051558","volume":"15","author":"B Puertas","year":"2023","unstructured":"Puertas B, Gonz\u00e1lez-Calle V, Sobejano-Fuertes E, et al. Novel agents as main drivers for continued improvement in survival in multiple myeloma. Cancers (Basel). 2023;15:1558.","journal-title":"Cancers (Basel)"},{"key":"291_CR13","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2217\/fon-2022-1018","volume":"19","author":"P Hlavacek","year":"2023","unstructured":"Hlavacek P, Schepart A, Silverstein AR, Petrilla AA, Johnson W, Schroeder A. Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma. Future Oncol. 2023;19:775\u201387.","journal-title":"Future Oncol"},{"key":"291_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/17474086.2023.2154648","volume":"16","author":"P Varughese","year":"2023","unstructured":"Varughese P, Smith R, Xue M, et al. Real-world treatment patterns and outcomes of triple-class treated patients with multiple myeloma in the United States. Expert Rev Hematol. 2023;16:65\u201374.","journal-title":"Expert Rev Hematol"},{"key":"291_CR15","first-page":"917","volume":"29","author":"J Yang","year":"2023","unstructured":"Yang J, Boytsov N, Carlson JJ, Barthold D. Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: a retrospective US claims database analysis. J Manag Care Spec Pharm. 2023;29:917\u201326.","journal-title":"J Manag Care Spec Pharm"},{"key":"291_CR16","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/blood.2022017635","volume":"143","author":"T Facon","year":"2024","unstructured":"Facon T, Leleu X, Manier S. How I treat multiple myeloma in geriatric patients. Blood. 2024;143:224\u201332.","journal-title":"Blood"},{"key":"291_CR17","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/pds.1926","volume":"19","author":"S Schneeweiss","year":"2010","unstructured":"Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf. 2010;19:858\u201368.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"291_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1185\/03007995.2015.1105202","volume":"32","author":"X Song","year":"2016","unstructured":"Song X, Cong Z, Wilson K. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Curr Med Res Opin. 2016;32:95\u2013103.","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"291_CR19","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1182\/blood-2019-123743","volume":"134","author":"R Fonseca","year":"2019","unstructured":"Fonseca R, Hagiwara M, Panjabi S, Yucel E, Buchanan J, Delea T. Economic burden of disease progression among transplant eligible multiple myeloma patients who have received at least one line of therapy in the US. Blood. 2019;134(Suppl 1):2211.","journal-title":"Blood"},{"key":"291_CR20","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","volume":"21","author":"S Usmani","year":"2016","unstructured":"Usmani S, Ahmadi T, Ng Y, et al. Analysis of real-world data on overall survival in multiple myeloma patients with \u22653 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;21:1355\u201361.","journal-title":"Oncologist"},{"key":"291_CR21","unstructured":"National Cancer Institute. SEER-Medicare: Comorbidity SAS Macros. 2023. Available at https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/calculation.html. Accessed 6 June 2024."},{"key":"291_CR22","unstructured":"Research Data Assistance Center. Death information in the research identifiable Medicare data. 2022. Available at https:\/\/resdac.org\/articles\/death-information-research-identifiable-medicare-data. Accessed 6 June 2024."},{"key":"291_CR23","unstructured":"U.S. Bureau of Labor Statistics. Consumer Price Index. Available at https:\/\/www.bls.gov\/cpi\/. Accessed 6 June 2024."},{"key":"291_CR24","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40487-021-00175-z","volume":"9","author":"S Jagannath","year":"2021","unstructured":"Jagannath S, Joseph N, He J, et al. Healthcare costs incurred by patients with multiple myeloma following triple class exposure (TCE) in the US. Oncol Ther. 2021;9:659\u201369.","journal-title":"Oncol Ther"},{"key":"291_CR25","unstructured":"Milliman. Commercial reimbursement benchmarking. 2022. Available at https:\/\/www.milliman.com\/en\/insight\/commercial-reimbursement-benchmarking. Accessed 6 June 2024."},{"key":"291_CR26","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022;36:1371\u20136.","journal-title":"Leukemia"},{"key":"291_CR27","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1080\/10428194.2022.2140284","volume":"64","author":"PF Wang","year":"2023","unstructured":"Wang PF, Yee CW, Gorsh B, et al. Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study. Leuk Lymphoma. 2023;64:398\u2013406.","journal-title":"Leuk Lymphoma"},{"key":"291_CR28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.clml.2022.11.008","volume":"23","author":"HC Lee","year":"2023","unstructured":"Lee HC, Ramasamy K, Weisel K, et al. Treatment patterns, survival, quality of life, and healthcare resource use among patients with triple-class refractory multiple myeloma in US clinical practice: findings from the Connect MM Disease Registry. Clin Lymphoma Myeloma Leuk. 2023;23:112\u201322.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"291_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.juro.2013.04.048","volume":"190","author":"EK Johnson","year":"2013","unstructured":"Johnson EK, Nelson CP. Values and pitfalls of the use of administrative databases for outcomes assessment. J Urol. 2013;190:17\u20138.","journal-title":"J Urol"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-024-00291-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-024-00291-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-024-00291-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T09:09:15Z","timestamp":1724058555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-024-00291-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,4]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["291"],"URL":"https:\/\/doi.org\/10.1007\/s40487-024-00291-6","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"type":"print","value":"2366-1070"},{"type":"electronic","value":"2366-1089"}],"subject":[],"published":{"date-parts":[[2024,8,4]]},"assertion":[{"value":"25 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Thomas E. Delea, Aaron Moynahan, and Natalia Sabater Anaya are employed by Avalere Health, which has received research funding and consulting fees from Regeneron Pharmaceuticals, Inc. and Sanofi for research projects related to multiple myeloma. Qiufei Ma, Glenn S. Kroog, Wenzhen Ge, Karen Rodriguez Lorenc, and Xue Song are employees of, and own Regeneron stock or stock options in, Regeneron Pharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Use of the data was governed by a Data Use Agreement (DUA) from CMS (DUA number: RSCH-2022-58036). The study protocol was reviewed and approved by the Advarra institutional review board (IRB Organization number [IORG]: 0000635. Protocol number: Pro00057753). This study is in compliance with the Declaration of Helsinki of 1964 and its later amendments. This study has also been reviewed and approved by an ethics committee as part of the IRB review conducted by Advarra. Given this study used deidentified, retrospectively captured clinical data, participant consent was not required. The IRB granted a Waiver of Consent for this study. No identifiable information is included in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}